Cerebrospinal fluid: identification of diagnostic markers for schizophrenia (Q37118995)

18 August 2017

1 reference

title

Cerebrospinal fluid: identification of diagnostic markers for schizophrenia (English)

1 reference

18 August 2017

0 references

0 references

0 references

2

Sabine Bahn

1 reference

18 August 2017

Emanuel Schwarz

1

1 reference

18 August 2017

1 March 2008

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

209-216

1 reference

18 August 2017

2

1 reference

Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Neuregulin 1 and susceptibility to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

CSF biomarker discovery using label-free nano-LC-MS based proteomic profiling: technical aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

S100B in brain damage and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Elevated plasma levels of S-100b protein in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Decreased S100-beta protein in schizophrenia: preliminary evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

The S-100: a protein family in search of a function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

3. Evidence for neurodevelopment disturbances in anterior cingulate cortex of post-mortem schizophrenic brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Elevated S100B levels do not correlate with the severity of encephalopathy during sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Serum S100B and antioxidant enzymes in bipolar patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Raised serum S100B levels after acute bone fractures without cerebral injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Elevated cerebrospinal fluid SNAP-25 in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for 'hypofrontality'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

SNAP-25 deficit and hippocampal connectivity in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Differential effects of SNAP-25 deletion on Ca2+ -dependent and Ca2+ -independent neurotransmission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

The biochemistry of neurotransmitter secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

The identification of a novel synaptosomal-associated protein, SNAP-25, differentially expressed by neuronal subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Risk factors for schizophrenia--all roads lead to dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Glycogen synthase kinase (GSK)-3beta levels and activity in a neurodevelopmental rat model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Low GSK-3 activity in frontal cortex of schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

GSK-3 parameters in lymphocytes of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Comparative proteome analysis revealed up-regulation of transthyretin in rat brain under chronic clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

The role of thyroid hormones in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Micrometer-sized particles in cerebrospinal fluid (CSF) in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

CSF metabolic and proteomic profiles in patients prodromal for psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Glutamate receptor dysfunction and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Novel neurotransmitters and their neuropsychiatric relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

A genetic variant of the serine racemase gene is associated with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Serine racemase protein expression in cortex and hippocampus in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Glutamate as a therapeutic target in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Proteomics analysis of prefractionated human lumbar cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Analysis of the human lumbar cerebrospinal fluid proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Lack of effect of mood stabilizers or neuroleptics on GSK-3 protein levels and GSK-3 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

Thyroid Function Screening in Newly Admitted Psychiatric Inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.8.2.209

21 January 2018

Identifiers

DOI

10.1586/14737159.8.2.209

1 reference

18 August 2017

1 reference

PubMed ID

18366307